This document outlines five investment options - Up, Stable, Choice, Hope, and Release - being considered by Tazer Corp for their pharmaceutical decision making project. It provides the R&D investment amount, success rate, potential revenue if successful, expected revenue, and expected profit for each option. The Choice option has the highest expected revenue of $770 million and expected profit of $170 million. The total proposed investment of $1,200 million and expected profit of $540 million is below the maximum investment limit.
This document outlines five investment options - Up, Stable, Choice, Hope, and Release - being considered by Tazer Corp for their pharmaceutical decision making project. It provides the R&D investment amount, success rate, potential revenue if successful, expected revenue, and expected profit for each option. The Choice option has the highest expected revenue of $770 million and expected profit of $170 million. The total proposed investment of $1,200 million and expected profit of $540 million is below the maximum investment limit.
This document outlines five investment options - Up, Stable, Choice, Hope, and Release - being considered by Tazer Corp for their pharmaceutical decision making project. It provides the R&D investment amount, success rate, potential revenue if successful, expected revenue, and expected profit for each option. The Choice option has the highest expected revenue of $770 million and expected profit of $170 million. The total proposed investment of $1,200 million and expected profit of $540 million is below the maximum investment limit.